Google
Trusted Resources: News & Events
Latest announcements and gatherings
Phase 3 Trial Recruiting to Test Rivipansel for Vaso-Occlusive Crisis in SCD
GlycoMimetics, in collaboration with Pfizer, is now enrolling participants for a Phase 3 clinical trial to test the effectiveness and safety of the drug candidate rivipansel (GMI-1070) for the treatment of vaso-occlusive crisis (VOC) in hospitalized patients with sickle cell disease (SCD).
“We can report that the Phase 3 program to evaluate rivipansel for vaso-occlusive sickle cell crisis, according to our partner Pfizer, remains on track for completion in the second half of 2018,” Rachel King, CEO of GlycoMimetics, said in a press release.
+myBinderRelated Content
-
Comparing Sickle Cell Disease Acute Pain Management in the Pediatric and Adult Emergency DepartmentBackground: Vasoocclusive pain leading ...
-
Chronic Opioid Therapy and Central Sensitization in Sickle Cell DiseaseChronic opioid therapy (COT) for chronic...
-
Vitamin D Supplements May Reduce Pain-related Emergency Room Visits in Children With SCDTaking vitamin D supplements may lower t...
-
Imara Reports Favorable Preclinical and Phase 1 Data on IMR-687 in Sickle Cell DiseaseImara Inc. today announced it will repor...
-
Sickle Cell Anemia Toddlers Benefit from Maximal Hydroxyurea Doses, Study FindsIntensifying treatment with hydroxyurea ...
-
Let Your Light Shine: Yoga & MeditationPiedmont Health Services and Sickle Cell...
-
Facebook Live: Stem Cells and Sickle Cell Diseasehttps://www.youtube.com/watch?v=IPzNx8i_...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.